Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
COPD
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
Do findings from the
STARR2
trial influence your approach?
Related Questions
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
Have you observed adverse mental health side effects in patients who start montelukast?
What is your approach to the work up and evaluation of loss of asthma control while on a biologic such as dupilumab?
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
How do you choose roflumilast vs ensifentrine in COPD patients with dyspnea despite adequate LABA + LAMA (+ ICS therapy where indicated)?